Predictors | ||||||
EA | NEA | |||||
ΔPC20AMP | ΔFEV1 | ΔACQ | ΔPC20AMP | ΔFEV1 | ΔACQ | |
FEV1 (baseline) | 0.308 | 0.613 | 0.254 | 0.305 | 0.849 | 0.387 |
FEV1 (LOC) | 0.426 | 0.818 | 0.411 | 0.315 | 0.865 | 0.379 |
BD response | 0.435 | 0.609 | 0.549 | 0.429 | 0.616 | 0.470 |
PD15HS | 0.538 | 0.597 | 0.558 | 0.500 | 0.401 | 0.641 |
PC20AMP | 0.686 | 0.691 | 0.710 | 0.656 | 0.708 | 0.646 |
Feno | 0.778 | 0.699 | 0.727 | 0.810 | 0.354 | 0.631 |
The outcomes were: change in airway hyper-responsiveness as measured by PC20AMP (ΔPC20AMP), change in FEV1 (ΔFEV1) and change in ACQ (ΔACQ) following 28+ days of inhaled fluticasone treatment in 60 patients with eosinophilic asthma (EA) (49 for PC20AMP) and 28 patients with non-eosinophilic asthma (NEA). An AUC of >0.7 is considered significant.
ACQ, Asthma Control Questionnaire; BD response, bronchodilator response; FEV1, forced expiratory volume in 1 s; Feno, fraction of exhaled nitric oxide; PC20AMP, provocation concentration of adenosine monophosphate causing a 20% fall in FEV1; PD15HS, provocation dose of hypertonic saline causing a 15% fall in FEV1.